Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) EBIT Margin (2019 - 2023)

Historic EBIT Margin for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to 18974.68%.

  • ADC Therapeutics' EBIT Margin rose 189787600.0% to 18974.68% in Q3 2023 from the same period last year, while for Sep 2023 it was 15372764.81%, marking a year-over-year decrease of 153726842000.0%. This contributed to the annual value of 58.9% for FY2022, which is 6257900.0% up from last year.
  • As of Q3 2023, ADC Therapeutics' EBIT Margin stood at 18974.68%, which was up 189787600.0% from 15666.65% recorded in Q2 2023.
  • ADC Therapeutics' 5-year EBIT Margin high stood at 18974.68% for Q3 2023, and its period low was 36157241.38% during Q3 2020.
  • Moreover, its 5-year median value for EBIT Margin was 401.43% (2022), whereas its average is 3435336.47%.
  • As far as peak fluctuations go, ADC Therapeutics' EBIT Margin plummeted by 2000000000bps in 2020, and later skyrocketed by 2000000000bps in 2021.
  • ADC Therapeutics' EBIT Margin (Quarter) stood at 16095.5% in 2019, then tumbled by -224542bps to 36157241.38% in 2020, then surged by 100bps to 369.08% in 2021, then crashed by -4168176bps to 15384394.97% in 2022, then surged by 100bps to 18974.68% in 2023.
  • Its last three reported values are 18974.68% in Q3 2023, 15666.65% for Q2 2023, and 271.55% during Q1 2023.